EVGN

Bullish

Experimental gut bacteria cancer therapy shows early anti-tumor signal

Evogene (Nasdaq: EVGN) announced the successful completion of a Phase 1 clinical study of BMC128, a rationally designed live bacterial product, in com...

Stock Titan 2 weeks ago 0

Bullish

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Evogene announced the successful completion of a Phase 1 clinical study of BMC128, a live bacterial product developed by its subsidiary Biomica, in co...

PR Newswire 2 weeks ago 0